Qingdao Baheal Medical INC. - Asset Resilience Ratio
Qingdao Baheal Medical INC. (301015) has an Asset Resilience Ratio of 4.28% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore 301015 total assets for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Qingdao Baheal Medical INC.'s Asset Resilience Ratio has changed over time. See Qingdao Baheal Medical INC. (301015) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Qingdao Baheal Medical INC.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Qingdao Baheal Medical INC. stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥366.30 Million | 4.28% |
| Total Liquid Assets | CN¥366.30 Million | 4.28% |
Asset Resilience Insights
- Limited Liquidity: Qingdao Baheal Medical INC. maintains only 4.28% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Qingdao Baheal Medical INC. Industry Peers by Asset Resilience Ratio
Compare Qingdao Baheal Medical INC.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jointown Pharmaceutical Group Co Ltd
SHG:600998 |
Medical Distribution | 0.08% |
|
Sigma Healthcare Ltd
AU:SIG |
Medical Distribution | 0.03% |
|
Ebos Group Ltd
AU:EBO |
Medical Distribution | 0.00% |
|
Paragon Care Ltd
AU:PGC |
Medical Distribution | 0.00% |
|
Mayne Pharma Group Ltd
AU:MYX |
Medical Distribution | 4.00% |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3 |
Medical Distribution | 4.48% |
|
Cyclopharm Ltd
AU:CYC |
Medical Distribution | 1.98% |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607 |
Medical Distribution | 4.21% |
Annual Asset Resilience Ratio for Qingdao Baheal Medical INC. (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Qingdao Baheal Medical INC..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.26% | CN¥264.46 Million ≈ $38.70 Million |
CN¥8.11 Billion ≈ $1.19 Billion |
+2.63pp |
| 2024-12-31 | 0.63% | CN¥44.99 Million ≈ $6.58 Million |
CN¥7.11 Billion ≈ $1.04 Billion |
+0.20pp |
| 2023-12-31 | 0.43% | CN¥27.62 Million ≈ $4.04 Million |
CN¥6.42 Billion ≈ $939.08 Million |
-1.21pp |
| 2022-12-31 | 1.64% | CN¥83.72 Million ≈ $12.25 Million |
CN¥5.12 Billion ≈ $748.50 Million |
+0.75pp |
| 2021-12-31 | 0.89% | CN¥40.77 Million ≈ $5.97 Million |
CN¥4.60 Billion ≈ $673.55 Million |
+0.02pp |
| 2020-12-31 | 0.86% | CN¥34.90 Million ≈ $5.11 Million |
CN¥4.05 Billion ≈ $592.75 Million |
+0.40pp |
| 2018-12-31 | 0.46% | CN¥12.00 Million ≈ $1.76 Million |
CN¥2.63 Billion ≈ $384.42 Million |
-- |
About Qingdao Baheal Medical INC.
Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Ha… Read more